Rasi Spells Out EMA’s Top 5 Priorities
Patient involvement, transparency, and support for innovative medicines are among the key objectives of the European Medicines Agency (EMA) over the next five years, according to Executive Director Prof. Guido Rasi.
Patient involvement, transparency, and support for innovative medicines are among the key objectives of the European Medicines Agency (EMA) over the next five years, according to Executive Director Prof. Guido Rasi.
At a press briefing December 9, Rasi highlighted the Agency’s five most urgent priories:
• Focus on research & development for medicines that address public health needs and have the potential to improve patients' lives so that innovation translates into public health benefits.
• Maintain transparency. For instance, EMA claims to be the first global regulator to allow researchers, academics, and the public access to the clinical data on which marketing authorizations are based.
• Increase patient involvement in the EMA’s work by ensuring the views and needs of the public are taken into account.
• Make use of all available evidence. Integrating all available data enables real-time monitoring of the safety and efficacy of medicines.
• Act as a global reference authority for the regulation of medicines. Development and manufacturing of medicines is now global and regulatory authorities cannot work in isolation.
To address these challenges, Rasi noted the need to strengthen cooperation with Member States, the European Commission and other European and international partners, and to bring communities and stakeholders involved closer together for a more holistic approach to medicines evaluation and surveillance across the whole lifespan of a medicine.
"I am confident that EMA, working closely with the national competent authorities in Member States, is ready to successfully address these new challenges,"said Rasi, who took office on November 16, 2015, having been nominated as Executive Director for a five-year mandate by the Management Board of the Agency on October 1, 2015.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
